- Home
- TOI vs AVIR Comparison
TOI vs AVIR Comparison
Compare TOI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- AVIR
- Stock Information
- Founded
- TOI 2007
- AVIR 2012
- Country
- TOI United States
- AVIR United States
- Employees
- TOI N/A
- AVIR 56
- Industry
- TOI Medical/Nursing Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TOI Health Care
- AVIR Health Care
- Exchange
- TOI Nasdaq
- AVIR Nasdaq
- Market Cap
- TOI 266.8M
- AVIR 252.5M
- IPO Year
- TOI N/A
- AVIR 2020
- Fundamental
- Price
- TOI $3.19
- AVIR $2.97
- Analyst Decision
- TOI
- AVIR Hold
- Analyst Count
- TOI 0
- AVIR 1
- Target Price
- TOI N/A
- AVIR $6.00
- AVG Volume (30 Days)
- TOI 1.7M
- AVIR 441.1K
- Earning Date
- TOI 05-14-2025
- AVIR 05-12-2025
- Dividend Yield
- TOI N/A
- AVIR N/A
- EPS Growth
- TOI N/A
- AVIR N/A
- EPS
- TOI N/A
- AVIR N/A
- Revenue
- TOI $403,152,000.00
- AVIR N/A
- Revenue This Year
- TOI $23.95
- AVIR N/A
- Revenue Next Year
- TOI N/A
- AVIR N/A
- P/E Ratio
- TOI N/A
- AVIR N/A
- Revenue Growth
- TOI 17.64
- AVIR N/A
- 52 Week Low
- TOI $0.13
- AVIR $2.46
- 52 Week High
- TOI $3.50
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- TOI 61.85
- AVIR 56.05
- Support Level
- TOI $2.82
- AVIR $2.78
- Resistance Level
- TOI $3.35
- AVIR $3.03
- Average True Range (ATR)
- TOI 0.37
- AVIR 0.17
- MACD
- TOI -0.00
- AVIR 0.03
- Stochastic Oscillator
- TOI 85.32
- AVIR 88.03
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).